FY2024 EPS Estimates for Masimo Increased by Zacks Research

Masimo Co. (NASDAQ:MASI) – Analysts at Zacks Research boosted their FY2024 EPS estimates for shares of Masimo in a research report issued on Tuesday, November 26th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical equipment provider will earn $4.00 per share for the year, up from their prior estimate of $3.84. The consensus estimate for Masimo’s current full-year earnings is $4.04 per share. Zacks Research also issued estimates for Masimo’s Q4 2024 earnings at $1.39 EPS, Q1 2025 earnings at $0.89 EPS, Q2 2025 earnings at $0.99 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $4.20 EPS and FY2026 earnings at $4.84 EPS.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.14. The firm had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.63 earnings per share.

Several other research firms have also recently weighed in on MASI. Wells Fargo & Company upped their price objective on shares of Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Piper Sandler lifted their price objective on shares of Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. BTIG Research upped their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $167.00.

Masimo Price Performance

Shares of NASDAQ MASI opened at $170.89 on Wednesday. The firm has a market capitalization of $9.15 billion, a P/E ratio of 117.86 and a beta of 0.97. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The stock’s 50-day simple moving average is $147.03 and its two-hundred day simple moving average is $129.03. Masimo has a twelve month low of $91.60 and a twelve month high of $178.27.

Hedge Funds Weigh In On Masimo

A number of large investors have recently added to or reduced their stakes in the business. NBC Securities Inc. boosted its position in Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 73 shares during the period. MML Investors Services LLC increased its stake in Masimo by 4.9% in the 3rd quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider’s stock worth $274,000 after purchasing an additional 96 shares during the period. Fifth Third Bancorp lifted its position in Masimo by 16.4% in the second quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider’s stock valued at $88,000 after purchasing an additional 98 shares during the last quarter. Oak Thistle LLC boosted its stake in shares of Masimo by 5.2% during the second quarter. Oak Thistle LLC now owns 2,079 shares of the medical equipment provider’s stock valued at $262,000 after purchasing an additional 103 shares during the period. Finally, GAMMA Investing LLC grew its holdings in shares of Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 111 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.